Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2

@Mike_Honey_ @RajlabN Cai et al https://t.co/CDcqMY7NSx believed that Amubarvimab / Romlusevimab can help against the Great China Wave, but BQ's and CH.1.1 escape these mabs https://t.co/LW0wDN9FB0

@EricTopol Some important things changed since the may publication. They hoped that Amubarvimab / Romlusevimab will help reduce the ICU crunch. But an L452 or R346 / N460 mutation combos disable both of these mabs, making them unfit for BQ's and many more

Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2 https://t.co/Wa8XsDVBYT

Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2: Monoclonal antibodies (mAbs) targeting the severe acute respiratory syndrome… #immunology https://t.co/QERy